Cardiovascular Magnetic Resonance Imaging Characteristics in Patients with Methamphetamine-associated Cardiomyopathy

Overview

Journal J Cardiovasc Magn Reson

Publisher Elsevier

Specialties Cardiology & Vascular Diseases
Radiology

Date 2022 Dec 1

PMID 36451214

Authors

Michael B Stokes

Fiona Thoi

Daniel J Scherer

Kyi T H Win

David M Kaye

Karen S Teo

Prashanthan Sanders

Affiliations

Soon will be listed here.

Abstract

Background: Methamphetamine-associated cardiomyopathy (MA-CMP) is an increasingly recognised aetiology of cardiomyopathy. Cardiovascular magnetic resonance (CMR) is a specialised cardiac imaging modality commonly used in assessment of cardiomyopathy. We aimed to identify specific CMR features associated with MA-CMP.

Methods: A retrospective cohort study of CMR scans was performed in a single centre between January 2015 and December 2020. Thirty patients with MA-CMP who had undergone CMR were identified. MA-CMP was defined as those with a history of significant methamphetamine use hospitalised with acute decompensated heart failure (other causes of cardiomyopathy excluded). A retrospective analysis of index admission CMRs was performed. All studies were performed on a 1.5 T CMR scanner.

Results: The mean age of MA-CMP patients was 43.7 ± 7.5 years, and 86.7% were male. The mean left ventricular (LV) volume obtained in this cohort was consistent with severe LV dilatation (LV end-diastolic volume (334 ± 99 ml); LV end-systolic volume: 269 ± 98 ml), whilst the right ventricular (RV) volume indicated moderate-to-severe dilatation (RV end-diastolic volume: 272 ± 91 ml; RV end-systolic volume: 173 ± 82 ml). Mean LV ejection fraction (20.9 ± 9.2%) indicated severe LV dysfunction, with moderate-to-severe RV dysfunction also detected (RV ejection fraction: 29.4 ± 13.4%). 22 patients (73.3%) had myocardial late gadolinium enhancement (LGE), of which 59.1% were located in the mid-wall, with all of these involving the interventricular septum. 22.7% displayed localised regions of sub-endocardial LGE in a variety of locations, and 18.2% had transmural regions of LGE that were located in the inferior and inferolateral segments. 6 patients (20%) had intracardiac thrombus (4 LV, 2 both LV and RV).

Conclusion: MA-CMP was associated with severe biventricular dilatation and dysfunction, with a high prevalence of intraventricular thrombus. This cohort study highlights that MA-CMP patients have a high prevalence of CMR findings.

Citing Articles

A Mechanistic Review on Toxicity Effects of Methamphetamine.

Ramli F, Rejeki P, Ibrahim N, Abdullayeva G, Halim S Int J Med Sci. 2025; 22(3):482-507.

PMID: 39898237 PMC: 11783064. DOI: 10.7150/ijms.99159.

Exploring Ambulatory Continuous Inotropes as a Bridge to Recovery in Advanced Heart Failure Secondary to Amphetamine-Induced Cardiomyopathy.

Babar A, Vallee-Marcotte B, Savin A, Bernier M, OConnor K, Senechal M CJC Open. 2025; 7(1):23-26.

PMID: 39872649 PMC: 11763879. DOI: 10.1016/j.cjco.2024.10.013.

References

Gulati A, Ismail T, Jabbour A, Ismail N, Morarji K, Ali A . Clinical utility and prognostic value of left atrial volume assessment by cardiovascular magnetic resonance in non-ischaemic dilated cardiomyopathy. Eur J Heart Fail. 2013; 15(6):660-70. DOI: 10.1093/eurjhf/hft019. View

Karch S . The unique histology of methamphetamine cardiomyopathy: a case report. Forensic Sci Int. 2011; 212(1-3):e1-4. DOI: 10.1016/j.forsciint.2011.04.028. View

Chen J . Methamphetamine-associated acute myocardial infarction and cardiogenic shock with normal coronary arteries: refractory global coronary microvascular spasm. J Invasive Cardiol. 2007; 19(4):E89-92. View

Reddy P, Ng T, Oh E, Moady G, Elkayam U . Clinical Characteristics and Management of Methamphetamine-Associated Cardiomyopathy: State-of-the-Art Review. J Am Heart Assoc. 2020; 9(11):e016704. PMC: 7428977. DOI: 10.1161/JAHA.120.016704. View

Lord K, Shenouda S, McIlwain E, Charalampidis D, Lucchesi P, Varner K . Oxidative stress contributes to methamphetamine-induced left ventricular dysfunction. Cardiovasc Res. 2010; 87(1):111-8. PMC: 2883898. DOI: 10.1093/cvr/cvq043. View

Richards J, Harms B, Kelly A, Turnipseed S . Methamphetamine use and heart failure: Prevalence, risk factors, and predictors. Am J Emerg Med. 2018; 36(8):1423-1428. DOI: 10.1016/j.ajem.2018.01.001. View

Japp A, Gulati A, Cook S, Cowie M, Prasad S . The Diagnosis and Evaluation of Dilated Cardiomyopathy. J Am Coll Cardiol. 2016; 67(25):2996-3010. DOI: 10.1016/j.jacc.2016.03.590. View

Ito H, Yeo K, Wijetunga M, Seto T, Tay K, Schatz I . A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse. Clin Cardiol. 2009; 32(6):E18-22. PMC: 3787838. DOI: 10.1002/clc.20367. View

Thomas I, Nishimura M, Ma J, Dickson S, Alshawabkeh L, Adler E . Clinical Characteristics and Outcomes of Patients With Heart Failure and Methamphetamine Abuse. J Card Fail. 2019; 26(3):202-209. DOI: 10.1016/j.cardfail.2019.10.002. View

10.

Parsai C, OHanlon R, Prasad S, Mohiaddin R . Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson. 2012; 14:54. PMC: 3436728. DOI: 10.1186/1532-429X-14-54. View

11.

Dickson S, Thomas I, Bhatia H, Nishimura M, Mahmud E, Tu X . Methamphetamine-Associated Heart Failure Hospitalizations Across the United States: Geographic and Social Disparities. J Am Heart Assoc. 2021; 10(16):e018370. PMC: 8475042. DOI: 10.1161/JAHA.120.018370. View

12.

Cruz Rodriguez J, Okajima K, Greenberg B . Management of left ventricular thrombus: a narrative review. Ann Transl Med. 2021; 9(6):520. PMC: 8039643. DOI: 10.21037/atm-20-7839. View

13.

Schurer S, Klingel K, Sandri M, Majunke N, Besler C, Kandolf R . Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy. JACC Heart Fail. 2017; 5(6):435-445. DOI: 10.1016/j.jchf.2017.02.017. View

14.

Pujol-Lopez M, Ortega-Paz L, Flores-Umanzor E, Perea R, Bosch X . Cardiac Magnetic Resonance as an Alternative to Endomyocardial Biopsy to Predict Recoverability of Left Ventricular Function in Methamphetamine- Associated Cardiomyopathy. JACC Heart Fail. 2017; 5(11):853-854. DOI: 10.1016/j.jchf.2017.08.009. View

15.

Zhao S, Kwong C, Swaminathan A, Gohil A, Crawford M . Clinical Characteristics and Outcome of Methamphetamine-Associated Pulmonary Arterial Hypertension and Dilated Cardiomyopathy. JACC Heart Fail. 2018; 6(3):209-218. DOI: 10.1016/j.jchf.2017.10.006. View

16.

Islam M, Kuroki H, Hongcheng B, Ogura Y, Kawaguchi N, Onishi S . Cardiac lesions and their reversibility after long term administration of methamphetamine. Forensic Sci Int. 1995; 75(1):29-43. DOI: 10.1016/0379-0738(95)01765-b. View

17.

Petersen S, Aung N, Sanghvi M, Zemrak F, Fung K, Paiva J . Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort. J Cardiovasc Magn Reson. 2017; 19(1):18. PMC: 5304550. DOI: 10.1186/s12968-017-0327-9. View

18.

He S, Matoba R, Fujitani N, Sodesaki K, Onishi S . Cardiac muscle lesions associated with chronic administration of methamphetamine in rats. Am J Forensic Med Pathol. 1996; 17(2):155-62. DOI: 10.1097/00000433-199606000-00014. View

19.

Iles L, Pfluger H, Lefkovits L, Butler M, Kistler P, Kaye D . Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011; 57(7):821-8. DOI: 10.1016/j.jacc.2010.06.062. View

20.

Perazzolo Marra M, De Lazzari M, Zorzi A, Migliore F, Zilio F, Calore C . Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy. Heart Rhythm. 2014; 11(5):856-63. DOI: 10.1016/j.hrthm.2014.01.014. View